Samaneh Tabaee1, Amirhossein Sahebkar2,3,4, Tayebe Aghamohammadi1, Manizhe Pakdel5, Maryam Dehabeh1, Reza Sobhani1, Mona Alidadi6, Muhammed Majeed7, Seyed Reza Mirhafez8. 1. Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. 2. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir. 3. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir. 4. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir. 5. Faculty of Nursing, Neyshabur University of Medical Sciences, Neyshabur, Iran. 6. Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Sabinsa Corporation, East Windsor, NJ, USA. 8. Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. mirhafezr@nums.ac.ir.
Abstract
BACKGROUND: Acute myocardial infarction (AMI) is a leading cause of death and disability worldwide. Previous investigations have demonstrated that curcumin has a cardioprotective effect and may improve myocardial injury. So this study was performed to assess whether supplementation with curcumin could diminish myocardial injury following AMI. METHODS: To conduct this randomized, double-blinded, and placebo-controlled clinical trial, seventy-two patients with acute myocardial infarction, aged 18-75 years, were enrolled and randomly divided into the active intervention and control groups. The active intervention group (n = 38) received curcumin capsules with piperine supplement (500 mg/day, 95% curcuminoids) for 8 weeks, whereas the control group (n = 34) received a placebo capsule. At the baseline and end of the study, ejection fraction was assessed, and blood samples were taken from all patients to measure the levels of cardiac troponin I(cTnI), lipid profile, FBG, HbA1C, liver enzymes, renal function parameters, and electrolytes. RESULTS: In this trial, curcumin supplementation significantly reduced the levels of HbA1C (-0.3 ± 2.2 vs. +1.1 ± 1.3, P = 0.002), LDL (-10.3 ± 20.7 vs. +0.2 ± 22.5, P = 0.039), ALT (-10.2 ± 28.5 vs. +7.3 ± 39.2, P = 0.029), and ALP (+6.4 ± 39.5 vs. +38.0 ± 69.0, P = 0.018) compared to the placebo group. Moreover, the serum concentration of HDL significantly improved in comparison with the placebo group (+4.5 ± 8.9 vs. -1.6 ± 7.7, P = 0.002). However, no substantial difference was perceived between the groups regarding the ejection fraction and serum levels of cTnI, FBG, renal function parameters, and electrolytes. CONCLUSION: Our results indicated that daily intake of 500 mg of curcumin capsules with piperine supplement for 8 weeks modified lipid profile, liver enzymes, and glycemic status, but did not have any effect on ejection fraction and serum concentration of cardiac troponin I, renal function parameters, and electrolytes in acute myocardial infarction patients.
BACKGROUND: Acute myocardial infarction (AMI) is a leading cause of death and disability worldwide. Previous investigations have demonstrated that curcumin has a cardioprotective effect and may improve myocardial injury. So this study was performed to assess whether supplementation with curcumin could diminish myocardial injury following AMI. METHODS: To conduct this randomized, double-blinded, and placebo-controlled clinical trial, seventy-two patients with acute myocardial infarction, aged 18-75 years, were enrolled and randomly divided into the active intervention and control groups. The active intervention group (n = 38) received curcumin capsules with piperine supplement (500 mg/day, 95% curcuminoids) for 8 weeks, whereas the control group (n = 34) received a placebo capsule. At the baseline and end of the study, ejection fraction was assessed, and blood samples were taken from all patients to measure the levels of cardiac troponin I(cTnI), lipid profile, FBG, HbA1C, liver enzymes, renal function parameters, and electrolytes. RESULTS: In this trial, curcumin supplementation significantly reduced the levels of HbA1C (-0.3 ± 2.2 vs. +1.1 ± 1.3, P = 0.002), LDL (-10.3 ± 20.7 vs. +0.2 ± 22.5, P = 0.039), ALT (-10.2 ± 28.5 vs. +7.3 ± 39.2, P = 0.029), and ALP (+6.4 ± 39.5 vs. +38.0 ± 69.0, P = 0.018) compared to the placebo group. Moreover, the serum concentration of HDL significantly improved in comparison with the placebo group (+4.5 ± 8.9 vs. -1.6 ± 7.7, P = 0.002). However, no substantial difference was perceived between the groups regarding the ejection fraction and serum levels of cTnI, FBG, renal function parameters, and electrolytes. CONCLUSION: Our results indicated that daily intake of 500 mg of curcumin capsules with piperine supplement for 8 weeks modified lipid profile, liver enzymes, and glycemic status, but did not have any effect on ejection fraction and serum concentration of cardiac troponin I, renal function parameters, and electrolytes in acute myocardial infarction patients.
Authors: J P Ottervanger; A W van 't Hof; S Reiffers; J C Hoorntje; H Suryapranata; M J de Boer; F Zijlstra Journal: Eur Heart J Date: 2001-05 Impact factor: 29.983
Authors: Derek S Chew; Huikuri Heikki; Georg Schmidt; Katherine M Kavanagh; Michael Dommasch; Poul Erik Bloch Thomsen; Daniel Sinnecker; Pekka Raatikainen; Derek V Exner Journal: JACC Clin Electrophysiol Date: 2018-03-01
Authors: S Fuchs; R Kornowski; R Mehran; L F Satler; A D Pichard; K M Kent; M K Hong; S Slack; G W Stone; M B Leon Journal: J Am Coll Cardiol Date: 1999-11-15 Impact factor: 24.094
Authors: S D Solomon; R J Glynn; S Greaves; U Ajani; J L Rouleau; F Menapace; J M Arnold; C Hennekens; M A Pfeffer Journal: Ann Intern Med Date: 2001-03-20 Impact factor: 25.391
Authors: Trygve S Hall; Thomas G von Lueder; Faiez Zannad; Patrick Rossignol; Kevin Duarte; Tahar Chouihed; Kenneth Dickstein; Dan Atar; Stefan Agewall; Nicolas Girerd Journal: Int J Cardiol Date: 2018-07-29 Impact factor: 4.164
Authors: E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald Journal: N Engl J Med Date: 1996-10-31 Impact factor: 91.245